Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. Currently, Gen9 offers multiple synthetic biology solutions for researchers who need high quality clonal, sequence-perfect DNA. Our award winning BioFab® process is remarkably flexible and very high throughput; allowing us to make the genes you need quickly at the highest quality available. Gen9 is Powering the Synthetic Biology Revolution.
Latest funding size
Time since last funding
|over 2 years|
|Agilent Technologies, Investors (1) UPDATE Other Investors, Draper Fisher Jurvetson (DFJ)|